Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Ann Oncol ; 32(1): 49-57, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33098995

RESUMEN

BACKGROUND: The efficacy and toxicity of olaparib as combination therapy in early breast cancer (BC) patients with homologous recombinant deficiency (HRD) [score high and/or germline (g) or tumour (t) BRCA1/2 mutation] is not well described. GeparOLA (ClinicalTrials.gov, NCT02789332) investigated olaparib in combination with paclitaxel in HER2-negative early BC with HRD. PATIENTS AND METHODS: Patients with untreated primary HER2-negative cT2-cT4a-d or cT1c with either cN+ or pNSLN+ or cT1c and triple-negative breast cancer (TNBC) or cT1c and Ki-67>20% BC with HRD were randomised either to paclitaxel (P) 80 mg/m2 weekly plus olaparib (O) 100 mg twice daily for 12 weeks or P plus carboplatinum (Cb) area under the curve 2 weekly for 12 weeks, both followed by epirubicin/cyclophosphamide (EC). Stratification factors were hormone receptor (HR) status (HR+ versus HR-) and age (<40 versus ≥40 years). The primary endpoint was pathological complete response (pCR; ypT0/is ypN0). A two-sided one-group χ2-test was planned to exclude a pCR rate of ≤55% in the PO-EC arm. Secondary end points were other pCR definitions, breast conservation rate, clinical/imaging response, tolerability and safety. RESULTS: A total of 107 patients were randomised between September 2016 and July 2018; 106 (PO N = 69; PCb N = 37) started treatment. Median age was 47.0 years (range 25.0-71.0); 36.2% had cT1, 61.0% cT2, 2.9% cT3, and 31.8% cN-positive tumours; grade 3 tumours: 86.8%; Ki-67>20%: 89.6%; TNBC: 72.6%; confirmed gBRCA1/2 mutation: 56.2%. The pCR rate with PO was 55.1% [90% confidence interval (CI) 44.5% to 65.3%] versus PCb 48.6% (90% CI 34.3% to 63.2%). Analysis for the stratified subgroups showed higher pCR rates with PO in the cohorts of patients <40 years and HR+ patients. CONCLUSION: GeparOLA could not exclude a pCR rate of ≤55% in the PO arm. PO was significantly better tolerated and the combination merits further evaluation.


Asunto(s)
Neoplasias de la Mama , Neoplasias de la Mama Triple Negativas , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/genética , Ciclofosfamida/efectos adversos , Recombinación Homóloga , Humanos , Persona de Mediana Edad , Terapia Neoadyuvante , Paclitaxel/efectos adversos , Ftalazinas , Piperazinas , Receptor ErbB-2/genética , Resultado del Tratamiento , Neoplasias de la Mama Triple Negativas/tratamiento farmacológico , Neoplasias de la Mama Triple Negativas/genética
2.
Ann Oncol ; 25(12): 2363-2372, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25223482

RESUMEN

BACKGROUND: The GeparQuinto study showed that adding bevacizumab to 24 weeks of anthracycline-taxane-based neoadjuvant chemotherapy increases pathological complete response (pCR) rates overall and specifically in patients with triple-negative breast cancer (TNBC). No difference in pCR rate was observed for adding everolimus to paclitaxel in nonearly responding patients. Here, we present disease-free (DFS) and overall survival (OS) analyses. PATIENTS AND METHODS: Patients (n = 1948) with HER2-negative tumors of a median tumor size of 4 cm were randomly assigned to neoadjuvant treatment with epirubicin/cyclophosphamide followed by docetaxel (EC-T) with or without eight infusions of bevacizumab every 3 weeks before surgery. Patients without clinical response to EC ± Bevacizumab were randomized to 12 weekly cycles paclitaxel with or without everolimus 5 mg/day. To detect a hazard ratio (HR) of 0.75 (α = 0.05, ß = 0.8) 379 events had to be observed in the bevacizumab arms. RESULTS: With a median follow-up of 3.8 years, 3-year DFS was 80.8% and 3-year OS was 89.7%. Outcome was not different for patients receiving bevacizumab (HR 1.03; P = 0.784 for DFS and HR 0.974; P = 0.842 for OS) compared with patients receiving chemotherapy alone. Patients with TNBC similarly showed no improvement in DFS (HR = 0.99; P = 0.941) and OS (HR = 1.02; P = 0.891) when treated with bevacizumab. No other predefined subgroup (HR+/HER2-; locally advanced (cT4 or cN3) or not; cT1-3 or cT4; pCR or not) showed a significant benefit. No difference in DFS (HR 0.997; P = 0.987) and OS (HR 1.11; P = 0.658) was observed for nonearly responding patients receiving paclitaxel with or without everolimus overall as well as in subgroups. CONCLUSIONS: Long-term results, in opposite to the results of pCR, do not support the neoadjuvant use of bevacizumab in addition to an anthracycline-taxane-based chemotherapy or everolimus in addition to paclitaxel for nonearly responding patients. CLINICAL TRIAL NUMBER: NCT 00567554, www.clinicaltrials.gov.


Asunto(s)
Inhibidores de la Angiogénesis/uso terapéutico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Sirolimus/análogos & derivados , Adulto , Inhibidores de la Angiogénesis/administración & dosificación , Anticuerpos Monoclonales Humanizados/administración & dosificación , Bevacizumab , Neoplasias de la Mama/metabolismo , Quimioterapia Adyuvante , Quimioterapia Combinada , Everolimus , Femenino , Humanos , Persona de Mediana Edad , Receptor ErbB-2/metabolismo , Sirolimus/administración & dosificación , Sirolimus/uso terapéutico , Análisis de Supervivencia
3.
Thorax ; 66(7): 579-84, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21270069

RESUMEN

BACKGROUND: Anaerobic bacteria are increasingly regarded as important in cystic fibrosis (CF) pulmonary infection. The aim of this study was to determine the effect of antibiotic treatment on aerobic and anaerobic microbial community diversity and abundance during exacerbations in patients with CF. METHODS: Sputum was collected at the start and completion of antibiotic treatment of exacerbations and when clinically stable. Bacteria were quantified and identified following culture, and community composition was also examined using culture-independent methods. RESULTS: Pseudomonas aeruginosa or Burkholderia cepacia complex were detected by culture in 24/26 samples at the start of treatment, 22/26 samples at completion of treatment and 11/13 stable samples. Anaerobic bacteria were detected in all start of treatment and stable samples and in 23/26 completion of treatment samples. Molecular analysis showed greater bacterial diversity within sputum samples than was detected by culture; there was reasonably good agreement between the methods for the presence or absence of aerobic bacteria such as P aeruginosa (κ=0.74) and B cepacia complex (κ=0.92), but agreement was poorer for anaerobes. Both methods showed that the composition of the bacterial community varied between patients but remained relatively stable in most individuals despite treatment. Bacterial abundance decreased transiently following treatment, with this effect more evident for aerobes (median decrease in total viable count 2.3×10(7) cfu/g, p=0.005) than for anaerobes (median decrease in total viable count 3×10(6) cfu/g, p=0.046). CONCLUSION: Antibiotic treatment targeted against aerobes had a minimal effect on abundance of anaerobes and community composition, with both culture and molecular detection methods required for comprehensive characterisation of the microbial community in the CF lung. Further studies are required to determine the clinical significance of and optimal treatment for these newly identified bacteria.


Asunto(s)
Antibacterianos/farmacología , Bacterias/efectos de los fármacos , Infecciones Bacterianas/tratamiento farmacológico , Fibrosis Quística/microbiología , Infecciones Oportunistas/tratamiento farmacológico , Adolescente , Adulto , Antibacterianos/uso terapéutico , Bacterias/clasificación , Bacterias/aislamiento & purificación , Bacterias Aerobias/clasificación , Bacterias Aerobias/efectos de los fármacos , Bacterias Aerobias/aislamiento & purificación , Bacterias Anaerobias/clasificación , Bacterias Anaerobias/efectos de los fármacos , Bacterias Anaerobias/aislamiento & purificación , Infecciones Bacterianas/complicaciones , Recuento de Colonia Microbiana , Fibrosis Quística/complicaciones , Fibrosis Quística/fisiopatología , Femenino , Volumen Espiratorio Forzado , Humanos , Masculino , Infecciones Oportunistas/complicaciones , Polimorfismo de Longitud del Fragmento de Restricción , Esputo/microbiología , Adulto Joven
4.
Infection ; 37(5): 424-31, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19756418

RESUMEN

PURPOSE: We hypothesized that a single intravenous (iv) tobramycine infusion (treatment B) would have equivalent anti-infectious efficacy in chronic Pseudomonas aeruginosa (PA) infection in cystic fibrosis (CF) as the commonly performed treatment of three doses (treatment A) . Toxicity and practicability may even be improved in the single-dose regimen. METHODS: This was a randomized crossover study comparing outcome after 14 and 35 days. The primary end-point was a decrease in the leukocyte count, and the secondary end-points were clinical and lung function parameters, Pseudomonas quantification in sputum, and inflammation markers (immunoglobulin G, C-reactive protein) in serum. 30 patients (20 female, mean age 11.2 years, mean age range 1.7-18.1 years) received elective 14-day courses of treatments A or B, followed by the alternative treatment after a mean interval of 37 (+/- 21) weeks. RESULTS: With the exception of PA density, there were no significant differences between both treatment strategies after 14 days of treatment. After 35 days of treatment, there were no significant changes in the leukocyte count and inflammation markers. Both treatment strategies reduced the bacterial load in the airways, as reflected by a decreased PA density in sputum. Nephrotoxicity was equal in both groups, with a transient slight elevation of urinary N-acetyl-beta-glucosaminidase concentrations. Standard audiometry tests revealed no evidence of a hearing impairment in any patient following therapy. Mean body weight increased during the study period by 0.5 kg. Forced expiratory volume increased by approximately 5% of the predicted volume, forced vital capacity increased by 2% of predicted capacity, and forced mid expiratory flow rate increased by 7% (A) or 4% (B) of the predicted normal value, although these changes were not statistically significant. CONCLUSION: We conclude that tobramycin given in a daily single dose (with the advantage of being more practical in a home environment) has an efficacy equal to that of three daily doses in terms of elective antipseudomonal therapy in clinically stable patients with CF.


Asunto(s)
Antibacterianos/administración & dosificación , Fibrosis Quística/complicaciones , Neumonía Bacteriana/tratamiento farmacológico , Infecciones por Pseudomonas/tratamiento farmacológico , Tobramicina/administración & dosificación , Adolescente , Niño , Preescolar , Estudios Cruzados , Femenino , Humanos , Lactante , Infusiones Intravenosas , Masculino , Neumonía Bacteriana/patología , Infecciones por Pseudomonas/patología , Resultado del Tratamiento
5.
Infection ; 37(5): 418-23, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19756419

RESUMEN

BACKGROUND/AIM: We hypothesized that a continuous 24-h infusion of 100 mg/kg per day ceftazidime (treatment C) would result in equivalent or even superior anti-infectious efficacy in chronic Pseudomonus aeruginosa (PA) infection in patients with cystic fibrosis (CF) in comparison to the usual application of 200 mg/kg per day ceftazidime in three doses (treatment T). METHODS: This was a randomized crossover study comparing outcome after 14 days and 35 days. Tobramycin administered once daily (10 mg/kg per day) was administered concomitantly in both groups. The primary end-point was a decrease in the leukocyte count, and the secondary endpoints were clinical and lung function parameters, Pseudomonas quantification in sputum, and inflammation markers (immunogloblulin [Ig] G, C-reactive protein [CRP]) in serum. All patients received antibiotics electively as 14-day courses on a regular basis, not for acute exacerbations. RESULTS: Fifty-six patients (29 females, mean patient age 14.4 years, age range 5-37) initially received treatments C or T, followed by the alternative treatment after a mean interval of 37 (+/- 21) weeks. After 2 weeks of antibiotic treatment, the overall study group showed significant improvements compared to baseline for body weight, leukocyte counts, CRP, forced expiratory volume in 1 s (FEV(1)), FVC (forced vital capacity), and bacterial load in the airways, with no significant differences between treatment groups. Both regimens were well tolerated. Three weeks after cessation of antimicrobial therapy, leukocytes and PA density had returned to pre-treatment values. CONCLUSION: We conclude that continuous or thrice-daily dosing of intravenous ceftazidime, both combined with once-daily tobramycin, are equally effective application regimens for elective antipseudomonal therapy in clinically stable patients with CF.


Asunto(s)
Antibacterianos/administración & dosificación , Ceftazidima/administración & dosificación , Fibrosis Quística/complicaciones , Neumonía Bacteriana/tratamiento farmacológico , Infecciones por Pseudomonas/tratamiento farmacológico , Adolescente , Adulto , Niño , Preescolar , Estudios Cruzados , Femenino , Humanos , Infusiones Intravenosas , Inyecciones Intravenosas , Masculino , Neumonía Bacteriana/patología , Infecciones por Pseudomonas/patología , Tobramicina/administración & dosificación , Resultado del Tratamiento , Adulto Joven
6.
Eur J Clin Microbiol Infect Dis ; 27(10): 891-9, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18629558

RESUMEN

Premature infants are vulnerable to severe respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) resulting in hospitalisation and the potential for longer-term respiratory morbidity. Whilst the severity and consequence of RSV LRTI are generally accepted and recognised in infants born

Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antivirales/uso terapéutico , Quimioprevención , Recien Nacido Prematuro , Infecciones por Virus Sincitial Respiratorio/prevención & control , Infecciones del Sistema Respiratorio/prevención & control , Anticuerpos Monoclonales Humanizados , Humanos , Recién Nacido , Palivizumab
7.
Clin Microbiol Infect ; 10(5): 452-8, 2004 May.
Artículo en Inglés | MEDLINE | ID: mdl-15113325

RESUMEN

The influence of the DNA extraction method on the sensitivity and specificity of bacteraemia detection by a 16S rRNA gene PCR assay was investigated. The detection limit of the assay was 5 fg with purified DNA from Escherichia coli or Staphylococcus aureus, corresponding to one bacterial cell. However, with spiked blood samples, the detection limits were 10(4) and 10(6) CFU/mL, respectively. The sensitivity of the S. aureus assay was improved to the level of the E. coli test with the addition of proteinase K to the commercial DNA extraction kit protocol. Ten (16.6%) of 60 amplification reactions were positive with templates isolated from sterile blood, while PCR reagent controls were negative, thereby indicating contamination during the DNA extraction process. Blood samples were spiked with serial dilutions of E. coli and S. aureus cells, and six PCR results were obtained from three extractions for each blood sample. A classification threshold system was devised, based on the number of positive reactions for each sample. Samples were deemed positive if at least four positive reactions were recorded, making it possible to avoid false-positive results caused by contamination. These results indicate that a comprehensive validation procedure covering all aspects of the assay, including DNA extraction, can improve considerably the validity of PCR assays for bacteraemia, and is a prerequisite for the meaningful detection of bacteraemia by PCR in the clinical setting.


Asunto(s)
Bacteriemia/diagnóstico , Escherichia coli/aislamiento & purificación , Genes de ARNr , Reacción en Cadena de la Polimerasa/métodos , ARN Ribosómico 16S/genética , Staphylococcus aureus/aislamiento & purificación , Bacteriemia/microbiología , Cartilla de ADN , ADN Bacteriano/análisis , ADN Bacteriano/aislamiento & purificación , ADN Ribosómico/genética , Escherichia coli/genética , Humanos , Reproducibilidad de los Resultados , Staphylococcus aureus/genética
8.
Biol Bull ; 154(3): 374-82, 1978 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20693366

RESUMEN

This study showed that there is a relationship between acid phosphatase levels and life cycle stages in the nematode, Panagrellus silusiae. Ten different isozymes of acid phosphatase were separated electrophoretically. Relative activity peaked at different stages in the life cycle for the different isozymes. Later in the life cycle, there is a general decrease in the relative activity of acid phosphatase itself, while there is a concurrent increase in the number of isozymes present. At least 97% of the acid phosphatase in P. silusiac is soluble (unbound). Acid phosphatase appears to be present in large quantities in the entire gastrointestinal tract, the excretory canals, and the reproductive system of mature Panagrellus silusiae.

9.
Emerg Med Serv ; 27(9): 69, 71-4, 1998 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-10185418

RESUMEN

The focus of the study was to prioritize six emergency medical service treatment factors in terms of their impact upon patient satisfaction in the prehospital setting. The six treatment areas analyzed were: EMS response time; medical care provided on scene; explanation of care by the provider; the provider's ability to reduce patient anxiety; the provider's ability to meet the patient's non-medical needs; and the level of courtesy/politeness shown by the EMS provider toward the patient. Telephone interviews were conducted with both patients and bystanders to obtain their perception of how well the system met their needs. The study analyzed how the six issues were rated and then evaluated the impact an individual's low score in a category had on that person's overall rating of the service provided. The overall satisfaction rating is not a calculated score, but an overall score specified by the respondent. The effect each issue had on the respondent's overall rating was determined by averaging the overall ratings for a category's low scorers, averaging the overall ratings for high scorers and then measuring the difference. Results of the study indicate that the factor with the greatest negative impact on patient satisfaction came from a perceived lack of crew courtesy and politeness. Respondents who indicated a fair to poor score in this category decreased their overall score by 60.2%. Ratings in other categories yielded the following results: When respondents rated the response time as fair to poor, their average overall rating showed an 18.4% decrease. When respondents rated the quality of medical care as fair to poor, their average overall rating showed a decrease of 22.6%. When the crew's ability to explain what was happening to the patient was rated as fair to poor, the average overall score dropped 33.6%. When the EMT's and medic's ability to reduce the patient's anxiety was rated fair to poor, average overall score declined by 32.6%. Finally, when the crew's ability to satisfy a patient's non-medical needs was rated as fair to poor, the average overall score diminished by 37.4%.


Asunto(s)
Servicios Médicos de Urgencia/normas , Satisfacción del Paciente/estadística & datos numéricos , Calidad de la Atención de Salud/clasificación , Servicios Médicos de Urgencia/estadística & datos numéricos , Servicio de Urgencia en Hospital , Encuestas de Atención de la Salud , Hospitales Universitarios , Humanos , Entrevistas como Asunto , Ciudad de Nueva York , Relaciones Profesional-Paciente , Calidad de la Atención de Salud/estadística & datos numéricos , Proyectos de Investigación
10.
Planta ; 75(1): 85-93, 1967 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24550018

RESUMEN

A dominant tumor-like condition recently isolated in a tomato hybrid is described from the viewpoint of morphogenesis. Tumors, consisting of masses of enlarged parenchymatous cells, generally appear on the ventral surface of the third leaf and the subsequently formed leaves of the hybrid derivatives. These outgrowths do not differentiate into teratomas. Abortive floral buds develop under greenhouse conditions and the tumorous plants are much dwarfed compared to the normal segregants of the same population. the same tumor genotype behaves differently under the field conditions: it grows and blossoms like the normal plants, setting fruits with viable seeds, and tumors fail to develop. Thus, tumor expression and general morphology of the tumor plants are greatly modified by environmental conditions.Tissue culture studies employing a variety of media have shown that tissues excised from tumor-producing plants are not autonomous with respect to growth hormones, nor are tissues from the non-tumorous segregants. Nevertheless, tissues from tumor and non-tumor genotypes show different growth requirements. Tumor and non-tumor tomatoes can thus be distinguished on the basis of in vitro growth responses, a result consistent with their different genetic constitution. Differentiation of buds or roots was not observed in either type of tissue.

11.
Res Commun Chem Pathol Pharmacol ; 18(2): 369-72, 1977 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-918353

RESUMEN

Male and female Long-Evans rats placed on a diet of Purina laboratory chow supplemented with 2.5 and 5.0% oxalic acid for a period of 70 days revealed decreased body weights and restricted growth rates. Ingestion of 5.0% oxalic acid depressed absolute organ weights of several visceral and endocrine tissues but enhanced the organ/body weight ratios of both male and female rats. Vaginal smears indicated disrupted estrous cycles.


Asunto(s)
Crecimiento/efectos de los fármacos , Oxalatos/farmacología , Reproducción/efectos de los fármacos , Animales , Peso Corporal/efectos de los fármacos , Dieta , Femenino , Masculino , Tamaño de los Órganos/efectos de los fármacos , Oxalatos/administración & dosificación , Ratas , Factores de Tiempo
12.
Am J Emerg Med ; 14(4): 364-8, 1996 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-8768156

RESUMEN

A retrospective study was conducted to determine the outcome of out-of-hospital cardiac arrests by one prehospital system in New York City from January, 1986, through December, 1993. The results were recorded consistent with the Utstein Style. Of 481 attempted patient resuscitations 406 were of cardiac etiology, with 382 patients having arrested prior to EMS arrival; their overall survival rate was 2.1% (8/382). Cardiac arrests were witnessed in 246 patients. Of the witnessed arrest patients found in ventricular fibrillation (96/246), the overall survival rate was 7.3% (7/96). Of the 7 survivors who were discharged from the hospital, 71.4% (5/7) had a good cerebral performance/good overall performance. Of 24 patients who arrested in the presence of EMS, the survival rate was 12.5% (3/24). This study confirms a poor survival rate for patients suffering out-of-hospital cardiac arrests in New York City.


Asunto(s)
Servicios Médicos de Urgencia , Paro Cardíaco/terapia , Anciano , Urgencias Médicas , Femenino , Paro Cardíaco/mortalidad , Humanos , Masculino , Ciudad de Nueva York , Resucitación , Estudios Retrospectivos , Tasa de Supervivencia , Factores de Tiempo , Resultado del Tratamiento
13.
Z Gesamte Inn Med ; 36(19): 727-30, 1981 Oct 01.
Artículo en Alemán | MEDLINE | ID: mdl-7303779

RESUMEN

For the purpose of testing extracardial haemodynamic effects of the calcium antagonist nifedipine (corinfar) in 15 patients with arterial obstructive disease and in a control group plethysmographic and doppler-sonographic measurements before and after oral application of the substance were performed. In these cases after the application of nifedipine a significant increase of the blood flow in the crural region developed. At the same time a slight decrease of the systolic pressure could be established at the upper and lower extremity. In patients with arterial obstructive disease these haemodynamic reactions had a less significant result. They correspond to an arterial vasodilatation with decrease of the peripheral resistance and simultaneously they explain a part of the antianginous effect of the calcium antagonist. The increase of the blood flow which is to be objectified after the application of nifedipine also in poststenotic areas might be of clinical importance particularly in the combined occurrence of atherosclerotically conditioned disturbances of the blood supply of the coronary and peripheral vascular system.


Asunto(s)
Arteriopatías Oclusivas/tratamiento farmacológico , Hemodinámica/efectos de los fármacos , Nifedipino/uso terapéutico , Piridinas/uso terapéutico , Velocidad del Flujo Sanguíneo , Presión Sanguínea/efectos de los fármacos , Humanos
14.
Z Gesamte Inn Med ; 36(15): 524-7, 1981 Aug 01.
Artículo en Alemán | MEDLINE | ID: mdl-7293286

RESUMEN

In 34 male patients with peripheral arterial occlusive disease of the lower extremities the individual responsibility to an intraarterial adenosine triphosphate infusion was tested with the help of Doppler-sonographic poststenotic measurements of the systolic blood pressure as well as comparatively to this by determination of the arterial blood-flow in rest in the region of the calf. While the greater part of the patients with occlusive disease reacted with a significant increase of the blood supply, nearly with the same frequency a decrease of pressure or no change could be established concerning the behaviour of the peripheral pressure. For the judgment of the efficacy of an intraarterial infusion treatment in the acute experiment plethysmographic measurements of the blood-flow are, therefore, more suitable and should be preferred to Doppler-sonographic pressure parameters. As to the controls of long-term therapy under conservative treatment as well as for the judgment of the success in the reconstructive surgery of vessels, however, the post-stenotic measurements of the pressure stood the test apart from further methods in clinical practice.


Asunto(s)
Adenosina Trifosfato/administración & dosificación , Arteriopatías Oclusivas/tratamiento farmacológico , Pierna/irrigación sanguínea , Vasodilatadores/administración & dosificación , Presión Sanguínea/efectos de los fármacos , Humanos , Inyecciones Intraarteriales , Masculino , Persona de Mediana Edad , Flujo Sanguíneo Regional/efectos de los fármacos , Ultrasonografía
15.
Ger J Ophthalmol ; 5(6): 417-21, 1996 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-9479529

RESUMEN

Staphylococcus aureus is one of the most common pathogens of bacterial corneal ulcers. It is generally believed that the first step necessary in the development of an infection involves adherence of bacteria to host tissue. The mechanisms by which staphylococci adhere to ocular epithelium have not yet been defined. An in vitro assay was used to measure binding of S. aureus and Streptococcus pyogenes to a cornea epithelial cell line. Reduction of the amount of cell-surface fibronectin by proteinase treatment decreased the adherence of S. pyogenes to a greater degree than that of S. aureus. The significantly higher number of staphylococci adhering to the cells as compared with S. pyogenes (P < 0.001) suggests the presence of additional binding sites for S. aureus. Using a thin-layer chromatogram overlay assay, we showed binding of S. aureus to various glycolipids extracted from corneal epithelial cells and corneal tissue. S. aureus was found to bind to gangliosides and asialo-GM1, whereas S. pyogenes did not bind to any of these complex lipids. The increased adherence potential of S. aureus due to the ability to bind to glycolipids may provide a selective advantage for S. aureus and explain the prevalence of this organism in bacterial corneal ulcers.


Asunto(s)
Adhesión Bacteriana , Epitelio Corneal/microbiología , Fibronectinas/metabolismo , Glucolípidos/metabolismo , Staphylococcus aureus/fisiología , Animales , Sitios de Unión , Cromatografía en Capa Delgada , Endopeptidasas/farmacología , Epitelio Corneal/química , Epitelio Corneal/efectos de los fármacos , Epitelio Corneal/metabolismo , Glucolípidos/aislamiento & purificación , Conejos , Streptococcus pyogenes/fisiología
16.
Z Gesamte Inn Med ; 41(19): 528-33, 1986 Oct 01.
Artículo en Alemán | MEDLINE | ID: mdl-3811439

RESUMEN

Clinical data and courses of the disease of 56 patients with non-Hodgkin-lymphomas of high malignancy were demonstrated. The age-depending summit of the frequency was between the 51st and 60th year of age, the age median was about 48 years. The initial remission rate three months after the beginning of the therapy was 66%. Out of the responders in 44% relapsed, in which cases 70% of the relapses developed in the first year after the beginning of treatment. After twelve months the survival rate was 0.52 and after 48 months 0.32. Patients with initial remission, with localized stages I and II (Ann Arbor) as well as with primarily extranodal manifestation and with histology of centroblastoma had a clear prognostic advantage. Initial B-symptomas, an advanced stage of the disease and a histology of immunoblastoma and lymphoblastoma as well were negatively correlated to the prognosis.


Asunto(s)
Linfoma no Hodgkin/diagnóstico , Adolescente , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Terapia Combinada , Femenino , Humanos , Linfoma no Hodgkin/patología , Linfoma no Hodgkin/terapia , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA